Department of Anesthesiology, Ganyu Hospital Affiliated to Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, China.
Department of Anesthesiology, Pain and Perioperative Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
J Clin Anesth. 2024 Dec;99:111608. doi: 10.1016/j.jclinane.2024.111608. Epub 2024 Sep 11.
This study aimed to investigate the effect of liposomal bupivacaine in transversus abdominis plane block (TAP) on recovery quality after cesarean delivery.
A randomized trial.
An operating room, a post-anesthesia care unit, and a hospital ward.
A total of 147 women scheduled for cesarean delivery under spinal anesthesia were enrolled and randomized to receive a TAP block with plain bupivacaine (bupivacaine group), liposomal bupivacaine (liposomal group), or a mixture of plain bupivacaine and liposomal bupivacaine (mixture group).
The bupivacaine group received bilateral TAP blocks with plain bupivacaine 50 mg alone. The liposomal group received bilateral TAP blocks with liposomal bupivacaine 266 mg alone. The mixture group received bilateral TAP blocks with plain bupivacaine 50 mg followed by liposomal bupivacaine 266 mg.
The primary outcome was the Quality of Recovery-15 (QoR - 15) score assessed 24 h postoperatively. Secondary outcomes encompassed the QoR - 15 score at 48 h post-surgery, the VAS pain score at rest and with movement at 24, 48, and 72 h postoperatively, opioid consumption within the 0-24 h and 24-48 h periods following surgery, as well as patient's satisfaction with analgesic.
The QoR - 15 score at 24 h postoperatively was significantly higher in both the liposomal group and the mixture group compared to the bupivacaine group. Specifically, the QoR - 15 score for the liposomal group versus the bupivacaine group (median [IQR]: 120 [107, 128] vs. 109 [104, 120]; median difference, 7; 95 % CI, 2 to 13; P = 0.011) and for the mixture group versus the bupivacaine group (median [IQR]: 122 [112, 128] vs. 109 [104, 120]; median difference, 9; 95 % CI, 4 to 14; P = 0.001). The QoR - 15 score in both the liposomal group and the mixture group were also higher than those in the bupivacaine group at 48 h postoperatively, though the difference was not clinically meaningful. Additionally, both the liposomal and mixture groups exhibited lower pain score at 24 h and 48 h postoperatively compared to the bupivacaine group, but no significant clinical differences were achieved in either pain scores or opioid consumption. Patients in both the liposomal and mixture groups reported higher satisfaction score with analgesia than those in the bupivacaine group.
TAP block using either liposomal bupivacaine or a mixture of plain bupivacaine and liposomal bupivacaine provided superior quality of recovery at 24 h after cesarean delivery compared to using plain bupivacaine alone.
本研究旨在探讨腹横肌平面阻滞(TAP)中应用脂质体布比卡因对剖宫产术后恢复质量的影响。
随机试验。
手术室、麻醉后监护病房和医院病房。
共纳入 147 名拟行椎管内麻醉剖宫产的女性患者,并随机分为三组:接受单纯布比卡因(布比卡因组)、脂质体布比卡因(脂质体组)或布比卡因和脂质体布比卡因混合物(混合物组)行 TAP 阻滞。
布比卡因组接受双侧 TAP 阻滞,单次给予 50mg 布比卡因;脂质体组接受双侧 TAP 阻滞,单次给予 266mg 脂质体布比卡因;混合物组接受双侧 TAP 阻滞,首先给予 50mg 布比卡因,随后给予 266mg 脂质体布比卡因。
主要结局指标为术后 24 小时的 QoR-15 评分。次要结局指标包括术后 48 小时的 QoR-15 评分、术后 24、48 和 72 小时的静息和运动时的 VAS 疼痛评分、术后 0-24 小时和 24-48 小时期间的阿片类药物消耗量,以及患者对镇痛的满意度。
术后 24 小时,脂质体组和混合物组的 QoR-15 评分均明显高于布比卡因组。具体而言,脂质体组与布比卡因组相比(中位数[IQR]:120[107,128]比 109[104,120];中位数差值,7;95%CI,2 至 13;P=0.011),混合物组与布比卡因组相比(中位数[IQR]:122[112,128]比 109[104,120];中位数差值,9;95%CI,4 至 14;P=0.001)。脂质体组和混合物组的 QoR-15 评分在术后 48 小时也高于布比卡因组,但差异无临床意义。此外,脂质体组和混合物组在术后 24 小时和 48 小时的疼痛评分均低于布比卡因组,但在疼痛评分或阿片类药物消耗方面均未达到显著的临床差异。与布比卡因组相比,脂质体组和混合物组的患者对镇痛的满意度评分更高。
与单独使用布比卡因相比,TAP 阻滞中应用脂质体布比卡因或布比卡因和脂质体布比卡因的混合物可在剖宫产术后 24 小时提供更好的恢复质量。